Medical journalist report of innovative biologics: DNA destabilization as a major source of metabolic pathology research findings of Mirko Beljanski, PhD, exhibit dramatic anticancer and anti-aging detoxifications

Townsend Letter for Doctors and Patients, Nov, 2003 by Morton Walker, Randall Walker

10. Stroun, M.; Anker, P.; Maurice, P.; Lyautey, J.; Lederrey, C.; Beljanski, M., Neoplastic characteristics of the DNA found in the plasma of cancer patients, Oncology 46:318-322, 1989.

11. Beljanski, M. & Beljanski, M.S., Three alkaloids as selective destroyers of the proliferative capacity of cancer cells. IRCS Medical Science, 12:587-588, 1984.

12. Nordau, C. & Beljanski, M.D. A Pioneer in Biomedicine: Concept, Theory, Applications. (New York City: Evi Liberty Corporation, 2001), pp 1-117.

13. Op. cit. Beljanski & Beljanski, 1984.

14. Op. cit. Nordau & Beljanski, 2001.

15. Beljanski, M.; Crochet, S.; Beljanski, M.S. PB100: A potent and selective inhibitor of human BCNU Resistant glioblastoma cell multiplication. Anticancer Research 13(6A):2301-2308, 1993.

16. Beljanski, M. & Crochet, S., The selective anticancer agents PB-100 and BG-8 are active against human melanoma cells, but do not affect nonmalignant fibroblasts. International Journal of Oncology 6:1143-1148, 1996.

17. Beljanski, M. The anticancer agent PB-100, selectively active on malignant cells, inhibits multiplication of sixteen malignant cell lines, even multidrug resistant. Genetics and Molecular Biology 23((1):29-33, 2000.

18. Beljanski, M. & Beljanski, M.S., Three alkaloids as selective destroyers of cancer cells in mice. Synergy with classic anticancer drugs. Oncology, 43:198-203, 1986.

19. Beljanski, M.; Plawecki, M.; Bourgarel, P.; Beljanski, M.S. Short chain RNA fragments as promoters of leucocyte and platelet genesis in animals depleted by anticancer drugs. In the Role of RNA in Development and Reproduction. Second International Symposium, 1980, April 25-30, pp. 79-113. Science Press Beijing. M.C. Niu and H.H. Chuang Eds. Van Nostrand Reinhold Company.

20. Plawecki, M. & Beljanski, M. Comparative study of Escherichia coli endotoxin, hydrocortisone and Beljanski leucocyte restorer activity in cyclophosphamide-treated rabbits, Proceedings of the Society for Experimental Biology and Medicine 168:408-413, 1981.

21. Beljanski, M.; Plawecki, M.; Bourgarel, P.; Beljanski, M.S. Leucocyte recovery with short-chain RNA fragments in cyclophosphamide-treated rabbits. Cancer Treatment Reports, 67:611-619, 1983.

22. Donadio, D.; Lorho, R.; Causse, J.E.; Nawrocki, T.; Beljanski, M. RNA fragments (RLB) and tolerance of cytostatic treatments of hematology: a preliminary study about two non-Hodgkin malignant lymphoma cases. Deutsche Zeitschrift fur Onkologie 23(2):33-35, 1991.

23. Causse, J.E.; Nawrocki, T.; Beljanski, M. Human skin fibrosis RNase search for a biological inhibitor-regulator. Deutsche Zeitschrift fur Onkologie 23(5):137-139, 1994.

24. Ibid.

25. Op. cit. Nordau & Beljanski, 2001.

26. Beljanski, M. A new approach to cancer therapy. Proceedings of the International Seminar: Traditional Medicine: a Challenge of the 21st Century, Nov. Calcutta (Ed.-in-Chief Biswapati Mukherjee), 1992, pp 7-9.

by Morton Walker, DPM with Randall Walker